Cormedix: Rezzayo and DefenCath Prophylaxis Upside Underscores Buy Rating and $13 DCF-Based Target

Analyst Brandon Folkes from H.C. Wainwright maintained a Buy rating on Cormedix and keeping the price target at $13.00.

Brandon Folkes has given his Buy rating due to a combination of factors that highlight Cormedix’s upside relative to its current valuation. He sees substantial revenue potential from Rezzayo in prophylaxis, supported by expert feedback that its dosing profile and expected patient outcomes could make it preferable to existing azole therapies in multiple high-need settings.

At the same time, Folkes views DefenCath’s role in TPN as a powerful economic and clinical driver, given the high infection burden and costly hospitalizations that could be avoided with effective prophylaxis. With shares trading near what he considers a valuation floor, he believes positive upcoming data from either Rezzayo or DefenCath could meaningfully re-rate the stock toward his $13 discounted cash flow–based price target, despite acknowledged commercial, clinical, reimbursement, and regulatory risks.

Folkes covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, Cormedix, and Pelthos Therapeutics. According to TipRanks, Folkes has an average return of 1.3% and a 40.17% success rate on recommended stocks.

In another report released today, Needham also maintained a Buy rating on the stock with a $15.00 price target.